HK Stock Market Move | CHERVON (02285) up by over 10% again, turning losses to profits for the whole year by up to US$120 million. Net profit margins in the second half of the year significantly improved.
Quanfeng Holdings (02285) further rose by over 10%, as of the time of writing, up 10.43% to HK$20.65, with a turnover of HK$25.43 million.
CHERVON (02285) rose by over 10%, reaching 10.43% as of press time, at 20.65 Hong Kong dollars, with a turnover of 254.324 million Hong Kong dollars.
On the news front, CHERVON previously announced a profit release, expecting a net profit of approximately 110 to 120 million US dollars for the 2024 fiscal year, compared to a loss of 37.2 million US dollars in the previous year. The main benefits are the end of destocking cycle in channels, revenue growth of about 25-30%; driven by the recovery in scale, favorable factors such as raw material costs, the gross profit margin has improved; and the continuous improvement in operating efficiency.
Caitong pointed out that the company expects a 25-30% increase in revenue for the full year, significantly exceeding the previously stated 20% target. Based on the full-year target, we estimate that the company's full-year revenue is expected to reach 1.72-1.79 billion US dollars, with H2 revenue expected to reach 0.90-0.97 billion US dollars, a growth rate of about 42-53%. According to the company's forecast, we calculate that the H2 net profit margin is expected to reach 5.0%-6.5%, excluding non-recurring factors related to the positioning adjustment of the company's German base, the net profit margin is expected to reach 7.5%-9.2%, significantly higher than the H1's 6.8%. The bank pointed out that the end of destocking cycle combined with interest rate cuts catalyzed, the company's performance entered an upward cycle.
Related Articles

Subsidiary products of Fuan Pharmaceutical (300194.SZ) included in the national medical insurance drug list.

Nanjing Hicin Pharmaceutical (300584.SZ)The company's injection of Landiolol hydrochloride has been included in the national medical insurance directory.

Livzon Pharmaceutical Group Inc. (000513.SZ): By the year 2025, the company will have a total of 194 products included in the national medical insurance catalog.
Subsidiary products of Fuan Pharmaceutical (300194.SZ) included in the national medical insurance drug list.

Nanjing Hicin Pharmaceutical (300584.SZ)The company's injection of Landiolol hydrochloride has been included in the national medical insurance directory.

Livzon Pharmaceutical Group Inc. (000513.SZ): By the year 2025, the company will have a total of 194 products included in the national medical insurance catalog.






